Protein, polynucleotide, recombinant vector, transformant, composition, method for detecting polyethylene terephthalate, and method for decomposing polyethylene terephthalate

A mutated protein with high binding affinity for PET addresses the challenge of PET detection and decomposition by facilitating efficient PET binding and degradation at elevated temperatures.

JP2024165590APending Publication Date: 2024-11-28NAT UNIV CORP SHIZUOKA UNIV
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2023081904
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-05-17
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

There is a limited understanding of substances that can effectively bind to polyethylene terephthalate (PET) for the purpose of detection and decomposition, which is a significant contributor to environmental pollution.

Method used

A protein with specific amino acid mutations, such as K13H, N15P, E22V, and D24G, is developed to have high binding affinity for PET, which can be used in conjunction with a polynucleotide, recombinant vector, and transformant to facilitate detection and degradation methods.

Benefits of technology

The protein effectively binds to PET at elevated temperatures, enabling efficient detection and degradation, with the potential for enhanced PET decomposition using a linked enzyme domain.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024165590000017
    Figure 2024165590000017
  • Figure 2024165590000018
    Figure 2024165590000018
  • Figure 2024165590000019
    Figure 2024165590000019
Patent Text Reader

Abstract

To provide a protein with binding affinity to PET; a polynucleotide encoding the protein; a recombinant vector and a transformant each containing the polynucleotide; a composition containing the protein; and methods for detecting and decomposing PET.SOLUTION: The present invention provides a protein with binding affinity to polyethylene terephthalate, containing an amino acid sequence that is at least 90% identical to an amino acid sequence with K13H, N15P, E22V, and D24G mutations based on the amino acid sequence of SEQ ID NO: 1, where the amino acid sequence contains the K13H, N15P, E22V, and D24G mutations; a polynucleotide encoding the protein; a recombinant vector and a transformant each containing the polynucleotide; a composition containing the protein; and methods for detecting and decomposing PET.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present disclosure relates to a protein, a polynucleotide, a recombinant vector, a transformant, a composition, a method for detecting polyethylene terephthalate, and a method for degrading polyethylene terephthalate. [Background technology]

[0002] There is growing emphasis on solving environmental pollution caused by plastics and building a sustainable society. Among these, polyethylene terephthalate (PET) accounts for 4% of the plastics produced domestically and is used in everyday items such as beverage bottles and clothing. In addition, composite materials with glass fibers and other materials are used as engineering plastics.

[0003] Various PET decomposition technologies aimed at the sustainable use of PET have been reported. For example, Patent Documents 1 to 4 report PET decomposition enzymes. [Prior art documents] [Patent documents]

[0004] [Patent Document 1] International Publication No. 2019 / 168811 [Patent Document 2] JP 2015-119670 A [Patent Document 3] International Publication No. 2012 / 099018 [Patent Document 4] Special Publication No. 2019-527060 Summary of the Invention [Problem to be solved by the invention]

[0005] It is known that used plastics break down into tiny particles when they are released into the environment and float in the water. Such plastics floating in the environment are called "microplastics." In order to address environmental pollution, technology to remove or decompose PET is desirable. To detect, remove, or decompose PET, it is useful to use substances that can bind to PET, but knowledge about substances that can bind to PET is limited. In view of the above circumstances, the present disclosure relates to providing a protein having binding ability to PET; a polynucleotide encoding the protein; a recombinant vector and a transformant comprising the polynucleotide; a composition comprising the protein; and a method for detecting and decomposing PET. [Means for solving the problem]

[0006] Means for solving the above problems include the following aspects. <1> The amino acid sequence has 90% or more sequence identity with an amino acid sequence having the mutations K13H, N15P, E22V, and D24G relative to the amino acid sequence of SEQ ID NO: 1, and contains the amino acid sequence having the mutations K13H, N15P, E22V, and D24G, A protein having the ability to bind to polyethylene terephthalate. <2> Ability to bind to polyethylene terephthalate at 60°C. <1> The protein according to claim 1. <3> Further comprising a labeling substance, <1> or <2> The protein according to claim 1. <4> The labeling substance is a fluorescent dye or a fluorescent protein. <3> The protein according to claim 1. <5> Further comprising an enzymatic domain, <1> ~ <4> 2. The protein according to any one of claims 1 to 11. <6> The enzyme domain is a polyethylene terephthalate degrading enzyme domain. <5> The protein according to claim 1. <7> <1> ~ <6> A polynucleotide comprising a base sequence encoding the protein according to any one of claims 1 to 5. <8> <7> A recombinant vector comprising the polynucleotide described in . <9> <8> A transformant comprising the recombinant vector according to claim 1. <10> <1> ~ <6> A composition comprising the protein described in any one of claims 1 to 4. <11> <3> or <4> 2. A method for detecting polyethylene terephthalate, comprising: contacting the protein according to claim 1 with polyethylene terephthalate; and detecting the labeling substance. <12> <6> A method for decomposing polyethylene terephthalate, comprising contacting the protein according to claim 1 with polyethylene terephthalate. Effect of the Invention

[0007] According to the present disclosure, there are provided a protein having PET-binding ability; a polynucleotide encoding the protein; a recombinant vector and a transformant comprising the polynucleotide; a composition comprising the protein; and a method for detecting and degrading PET. [Brief description of the drawings]

[0008] [Figure 1] The gene map of PfChBD2-fADL-1e is shown. [Diagram 2] 1 shows an overview of the biopanning process. [Diagram 3] The figures show the number of colonies formed on 2xYT agar medium supplemented with 50 µg / mL kanamycin inoculated with the wash and eluate from the second and third rounds of biopanning. [Figure 4] The three-dimensional structures of PfChBD2 (PDB ID: 2CWR) and the PfChBD2-K270T-N272P-E279L-D281R, PfChBD2-K270P-E279L-D281W, and PfChBD2-K270H-N272P-E279V-D281G mutants predicted by AlphaFold2 are shown. The hatched areas indicate the positions of the mutated K270, N272, E279, and D281. a: The entire structure is shown. b: An enlarged view of the mutated site is shown. [Diagram 5] The gene map of stagRFP-PfChBD2-TEV-His is shown. [Figure 6] The amount of PET binding in the wild type (WT) and K270H-N272P-E279V-D281G mutant of PfChBD2 is shown. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0009] Hereinafter, the form for carrying out the embodiment of the present disclosure will be described in detail. However, the embodiment of the present disclosure is not limited to the following embodiment. In the following embodiment, the components (including element steps, etc.) are not essential unless specifically stated. The same applies to the numerical values ​​and their ranges, and they do not limit the embodiment of the present disclosure.

[0010] In the present disclosure, the term "step" includes not only a step that is independent of other steps, but also a step that cannot be clearly distinguished from other steps as long as the purpose of the step is achieved. In the present disclosure, a numerical range indicated using "~" includes the numerical values ​​before and after "~" as the minimum and maximum values, respectively. In the present disclosure, even if an element is described in the singular form, it does not exclude the presence of a plurality unless there is a technical contradiction, unless otherwise expressly stated. In the numerical ranges described in the present disclosure in stages, the upper or lower limit value described in one numerical range may be replaced with the upper or lower limit value of another numerical range described in stages. In addition, in the numerical ranges described in the present disclosure, the upper or lower limit value of the numerical range may be replaced with a value shown in the examples.

[0011] In the present disclosure, the "identity" of amino acid sequences refers to the percentage of the number of identical amino acid residues in the total number of amino acid residues when two amino acid sequences to be compared are aligned, with appropriate gaps inserted into one or both as necessary, so that the number of identical amino acid residues is maximized. Alignment can be evaluated using the default parameters of BLAST.

[0012] In the present disclosure, "having X% or more sequence identity" with a reference amino acid sequence means that the entire length or a portion of the amino acid sequence to be compared has X% or more sequence identity to the entire length of the reference amino acid sequence.

[0013] In this disclosure, amino acid residues may be represented by the following single letter code in brackets: Alanine (A), Arginine (R), Asparagine (N), Aspartic acid (D), Cysteine ​​(C), Glutamine (Q), Glutamic acid (E), Glycine (G), Histidine (H), Isoleucine (I), Leucine (L), Lysine (K), Methionine (M), Phenylalanine (F), Proline (P), Serine (S), Threonine (T), Tryptophan (W), Tyrosine (Y), Valine (V).

[0014] In the present disclosure, amino acid mutations in a peptide or protein may be represented in the following order: the single letter code of the amino acid before the mutation, the amino acid position number from the N-terminus, and the single letter code of the amino acid after the mutation. For example, "having a K13H mutation in the amino acid sequence of SEQ ID NO: 1" means that the 13th lysine from the N-terminus of SEQ ID NO: 1 has been replaced with histidine.

[0015] In the present disclosure, a "protein comprising an amino acid sequence of X" means that all or a part of the amino acid sequence of the protein is the amino acid sequence of X. That is, the protein may consist of only the amino acid sequence of X, or may have, in addition to the amino acid sequence of X, additional sequences (e.g., sequences for protein expression and recovery, such as signal sequences, tag sequences, etc.; sequences for protein labeling; other domains, etc.) at either or both of the N-terminus and C-terminus of the amino acid of X.

[0016] <Protein> The protein of the present disclosure has 90% or more sequence identity with an amino acid sequence having the K13H, N15P, E22V, and D24G mutations relative to the amino acid sequence of SEQ ID NO: 1, and contains the amino acid sequence having the K13H, N15P, E22V, and D24G mutations, and has the ability to bind to PET.

[0017] SEQ ID NO:1: TTPVPVSGSL EVKVNDWGSG AEYDVTLNLD GQYDWTVKVK LAPGATVGSF WSANKQEGNG YVIFTPVSWN KGPTATFGFI VNGPQGDKVE EITLEINGQV I

[0018] The amino acid sequence of SEQ ID NO: 1 represents the amino acid sequence of the CBM2 family chitin-binding domain of thermostable chitinase derived from Pyrococcus furiosus (hereinafter, also referred to as "PfChBD2"). The inventors found that the above-mentioned four mutations in the amino acid sequence of PfChBD2 improve the binding ability to PET. A protein having such four mutations may be useful as a protein having the binding ability to PET.

[0019] The protein of the present disclosure includes an amino acid sequence having 90% or more sequence identity with an amino acid sequence having K13H, N15P, E22V, and D24G mutations with respect to the amino acid sequence of SEQ ID NO: 1, and preferably has 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity with an amino acid sequence having K13H, N15P, E22V, and D24G mutations with respect to the amino acid sequence of SEQ ID NO: 1. The amino acid sequences having K13H, N15P, E22V, and D24G mutations with respect to the amino acid sequence of SEQ ID NO: 1 are shown below.

[0020] SEQ ID NO:2: TTPVPVSGSL EVHVPDWGSG AVYGVTLNLD GQYDWTVKVK LAPGATVGSF WSANKQEGNG YVIFTPVSWN KGPTATFGFI VNGPQGDKVE EITLEINGQV I

[0021] The protein of the present disclosure may or may not contain mutations other than K13H, N15P, E22V, and D24G with respect to SEQ ID NO: 1, as long as it satisfies the above sequence identity. For example, the protein of the present disclosure may contain an amino acid sequence in which one or more amino acids are deleted, substituted, or added with respect to SEQ ID NO: 2, as long as it contains the mutations K13H, N15P, E22V, and D24G. In this case, the number of amino acids to be deleted, substituted, or added is not limited as long as the protein has the ability to bind to PET, and may be, for example, 1 to 6, 1 to 5, 1 to 4, 1 to 3, 1 to 2, or 1. The position of the amino acid to be deleted, substituted, or added may be, for example, one or more ranges selected from the group consisting of 1 to 12, 14, 16 to 21, 23, or 25 to 101 from the N-terminus of SEQ ID NO: 1.

[0022] The protein of the present disclosure may have an additional amino acid sequence at the N-terminus or C-terminus. The additional amino acid sequence may be an additional sequence for producing the protein of the present disclosure by recombinant technology. Such additional sequences may include an amino acid that serves as the initiation point of protein synthesis (such as an N-terminal methionine residue), an N-terminal signal sequence (such as a signal sequence for protein secretion in E. coli), a tag sequence (such as a histidine tag, GST tag, or FLAG tag), a protease recognition sequence (such as a TEV protease recognition sequence), and the like. The protein of the present disclosure may also contain a labeling substance and / or an enzyme domain, which will be described later.

[0023] The protein of the present disclosure may consist of 101 to 1000 amino acids, may consist of 101 to 500 amino acids, or may consist of 101 to 300 amino acids.

[0024] The protein of the present disclosure has a binding ability to PET. The conditions under which the protein of the present disclosure has a binding ability to PET are not particularly limited, and for example, the protein may have a binding ability to PET under any temperature condition. The protein of the present disclosure has a binding ability to PET at, for example, 20°C, 25°C, 30°C, 35°C, 40°C, 45°C, 50°C, 55°C, 60°C, or 65°C. Preferably, the protein of the present disclosure has a binding ability to PET at least at 25°C, more preferably at least at 25°C to 40°C, even more preferably at least at 25°C to 50°C, and particularly preferably at least at a temperature range of 25°C to 60°C. Furthermore, for example, the protein of the present disclosure may have PET-binding ability under any pH condition. The protein of the present disclosure has PET-binding ability, for example, at pH 4, 5, 6, 7, 8, 9, or 10. Preferably, the protein of the present disclosure has PET-binding ability at least at pH 8, more preferably at least at pH 6-8, even more preferably at least at pH 5-9, and particularly preferably at least at pH 4-10.

[0025] In the present disclosure, the ability to bind to PET is confirmed by at least one of the following methods. If binding is confirmed by any of the following methods, the test protein is determined to have the ability to bind to PET. 1. Method of heat-treating bound PET and analyzing the amount of bound protein by SDS-PAGE: PET film or PET powder is mixed with the test protein and reacted, then centrifuged to obtain a PET precipitate, which is then washed. The washed PET film or PET powder is suspended in a sample buffer and heated to denature and recover the protein bound to PET. The amount of bound protein is analyzed by SDS-PAGE. Alternatively, the amount of protein in the supernatant with and without PET is compared by SDS-PAGE to calculate the amount of protein that has been reduced by binding to PET, and the amount of bound protein is analyzed. 2. Decrease in absorbance at 280 nm of the supernatant after reaction: A thoroughly washed PET film or PET powder is mixed with a protein solution containing the protein to be tested to carry out a binding reaction. The supernatant is collected and the decrease in absorbance at 280 nm due to the protein is measured to estimate the amount of protein in the solution that has been reduced by binding to PET.

[0026] In one embodiment, the protein of the present disclosure may further comprise a labeling substance.The labeling substance is a substance that serves as a label that allows the protein of the present disclosure to be detected.When the protein of the present disclosure comprises a labeling substance, the protein of the present disclosure that is bound to PET can be easily detected. Examples of labeling substances include fluorescent dyes, fluorescent proteins, alkynyl groups (for example, alkynyl groups as tags for Raman spectroscopy), etc. Among these, fluorescent dyes and fluorescent proteins are preferred. Examples of fluorescent dyes include fluoresceins, azos, rhodamines, coumarins, pyrenes, and cyanines. Examples of fluorescent proteins include red fluorescent protein (RFP), orange fluorescent protein (mOrange), yellow fluorescent protein (YFP), green fluorescent protein (GFP), cyan fluorescent protein (CFP), blue fluorescent protein (BFP), etc. As a red fluorescent protein, for example, stagRFP is known (Nature Communications (2020) 11:1848).

[0027] In one embodiment, the protein of the present disclosure may further include an enzyme domain. An "enzyme domain" is a domain having an enzyme activity. In this embodiment, the enzyme domain is a domain linked to a domain (hereinafter also referred to as "PET binding domain") that has "90% or more sequence identity with an amino acid sequence having the mutations K13H, N15P, E22V, and D24G relative to the amino acid sequence of SEQ ID NO: 1, contains the amino acid sequence having the mutations K13H, N15P, E22V, and D24G, and has the ability to bind to PET." In other words, the protein of the present disclosure may be a protein in which an enzyme domain and a PET binding domain are linked.

[0028] The type of enzyme in the enzyme domain is not particularly limited, and examples thereof include a PET-degrading enzyme domain, etc. For example, when the protein of the present disclosure is a protein in which a PET-degrading enzyme domain and a PET-binding domain are linked, the PET-degrading enzyme domain can degrade PET while ensuring binding to PET by the PET-binding domain, which is considered to enable efficient decomposition of PET.

[0029] Various enzymes are known as PET-degrading enzymes, and examples of such enzymes are described in WO 2019 / 168811; JP 2015-119670 A; WO 2012 / 099018 A; JP 2019-527060 A; Meilleur, C.; Hupe, JF; Juteau, P.; Shareck, F. Isolation and Characterization of a New Alkali-Thermostable Lipase Cloned from a Metagenomic Library. J. Ind. Microbiol. Biotechnol. 2009, 36, 853-61; Danso, D.; Schmeisser, C.; Chow, J.; Zimmermann, W.; Wei, R.; Leggewie, C.; Li, X.; Hazen, T.; Streit, WR New Insights into the Function and Global Distribution of Polyethylene Terephthalate (Pet)-Degrading Bacteria and Enzymes in Marine and Terrestrial Metagenomes. Appl. Environ. Microbiol. 2018, 84, No. e02773-17, etc.

[0030] The optimum pH for the PET hydrolysis activity of the PET degrading enzyme (the pH at which the activity is highest) is not particularly limited, and is preferably near neutral in practical use. For example, the optimum pH is preferably pH 5.0 to 9.5, more preferably pH 5.5 to 9.0, and may be pH 6.0 to 8.0.

[0031] Since PET has a glass transition temperature around 70° C. and it is expected that the decomposition efficiency will increase when PET is decomposed at a high temperature, the optimum temperature for the PET hydrolysis activity of the PET decomposition enzyme is preferably more than 60° C., and more preferably 65° C. or higher, at pH 7. Furthermore, from the viewpoint of performing the decomposition with low energy within a range in which the decomposition of PET is promoted, the optimum temperature for the PET hydrolysis activity of the PET decomposition enzyme may be 90° C. or lower, 85° C. or lower, or 80° C. or lower. The optimum temperature is measured as follows: Two amorphous PET disks (thickness 0.25 mm, total surface area 0.32 cm2) are 2 To each of the samples (4.0 mg total mass), 250 μL of 0.1 μM protein in 50 mM sodium phosphate solution (pH 7.0) was added and incubated at each temperature for 60 minutes. The degradation product concentration was analyzed by HPLC, and the activity value was obtained by dividing the total degradation product concentration by the protein concentration and the reaction time.

[0032] Decomposition products of PET by hydrolysis include bis(hydroxyethyl)terephthalate (BHET), mono(hydroxyethyl)terephthalate (MHET), terephthalic acid (TPA), and ethylene glycol (EG). The decomposition products of PET by the PET-degrading enzyme may be all of these, a part of these, or a partial decomposition product in which these are linked together.

[0033] The melting temperature (Tm) of the PET-degrading enzyme is preferably 70.0° C. or higher, more preferably 72.0° C. or higher, and even more preferably 74.0° C. or higher. Since it is desirable to perform the decomposition with low energy within a range that promotes the decomposition of PET, the melting temperature (Tm) of the PET-degrading enzyme may be 100.0° C. or lower, 95.0° C. or lower, or 90.0° C. or lower. In this disclosure, the melting temperature (Tm) of a protein is measured by circular dichroism (CD) spectroscopy as follows: Prepare a 13 μM protein solution in 10 mM sodium phosphate solution (pH 7.0). Measure the CD spectrum of the protein at 250-200 nm at 20° C. Monitor the protein signal at 230 nm while heating the protein from 20° C. at a rate of 1° C. / min. Measure the CD spectrum of the denatured protein at 250-200 nm at 95° C. Estimate the Tm of the protein by curve fitting the temperature dependence of the signal at 230 nm.

[0034] <Polynucleotides, recombinant vectors, and transformants> The polynucleotides of the present disclosure include nucleotide sequences that encode the proteins of the present disclosure. The recombinant vector of the present disclosure comprises the polynucleotide. The transformant of the present disclosure contains the recombinant vector.

[0035] The polynucleotide may be any polynucleotide that encodes the protein of the present disclosure. The nucleic acid sequence of the polynucleotide may be changed within the range of degeneracy of codons. When introducing the recombinant vector into a host to obtain a transformant and express a protein, it is preferable to adopt the codons that are frequently used in the host.

[0036] The recombinant vector may be any recombinant vector capable of expressing the protein of the present disclosure. Preferred recombinant vectors include plasmids, phages, etc. The expression vector has a promoter necessary for expression, and may have other components such as a terminator, a selection marker (e.g., drug resistance gene), etc. The host is not particularly limited as long as it can express the protein of the present disclosure, and is selected together with the recombinant vector to be used. As the host, it is convenient to use a microbial cell, and for example, a prokaryote (e.g., Escherichia coli), a eukaryote (e.g., yeast), etc. may be used. When producing a protein using an expression vector and a host, conditions for transformation, expression, and recovery can employ methods well-known to those skilled in the art.

[0037] <Composition> The composition of the present disclosure contains the protein of the present disclosure. The protein of the present disclosure may be contained in the composition in an unpurified state (for example, a state containing a host that expresses the protein, or a state containing a crude protein solution secreted from a host that expresses the protein), or in a purified state, and is preferably contained in the composition in a purified state.

[0038] In addition to the protein of the present disclosure, the composition of the present disclosure may contain a buffer solution suitable for protein stabilization. As the buffer solution, a buffer solution that maintains the liquidity of the composition near neutrality is preferable, and examples include phosphate buffer, sodium phosphate buffer, Tris-HCl buffer, HEPES, and the like. In addition to the protein and buffer solution of the present disclosure, the composition of the present disclosure may contain additives such as stabilizers.

[0039] <Method for detecting PET> In one embodiment, there is provided a method for detecting PET, which includes contacting the protein of the present disclosure containing a labeling substance with PET and fluorescently detecting the labeling substance. According to such a method, since the protein of the present disclosure binds to PET, PET can be efficiently detected by detecting the labeling substance. Details of the labeling substance are as described above.

[0040] <Method for decomposing PET> In one embodiment, there is provided a method for decomposing PET, which includes contacting the protein of the present disclosure containing a PET-degrading enzyme domain with PET. According to such a method, since the protein of the present disclosure binds to PET, PET can be efficiently decomposed. The temperature and reaction time for decomposing PET can be appropriately set within a range suitable for PET decomposition. Details of the PET-degrading enzyme domain are as described above.

Examples

[0041] Next, the embodiments of the present disclosure will be specifically described using examples, but the embodiments of the present disclosure are not limited to these examples.

[0042] 1. Background and Objectives In nature, some carbohydrate-binding modules (CBMs) found in cellulases and chitinases improve the binding ability of enzymes to crystalline cellulose and chitin, thereby improving their decomposition activity. In the CAZy (Carbohydrate-Active EnZymes) database, CBM families are classified based on amino acid sequence homology, and there are currently 96 CBM families. There are three types of CBMs: type A, which can bind to insoluble carbohydrates such as crystalline cellulose; type B, which can bind to the interior of various glycans except insoluble substrates; and type C, which can bind to the terminals of glycans. In particular, type A CBMs form a planar interaction surface because the aromatic residues exposed on the surface bind to the flat surfaces of crystalline cellulose and chitin. It has been suggested that CBMs may have an affinity for PET, and that the exposed aromatic amino acid residues of type A CBMs play an important role in the interaction with PET. It is thought that the exposed aromatic amino acids of type A CBMs can interact with the PET surface, just like flat crystalline cellulose and chitin. Therefore, one strategy to improve the binding ability of enzymes to PET is to fuse CBMs to the enzymes.

[0043] The CBM2 family chitin-binding domain (PfChBD2) of thermostable chitinase from Pyrococcus furiosus is a CBM of type A. PfChBD2 is highly thermostable and has been confirmed to maintain its structure even at 85°C, which is higher than the glass transition temperature of PET, making it suitable as a template structure for the PET-binding domain.

[0044] In this study, we attempted to develop a protein with PET-binding ability by artificially evolving PfChBD2 using saturation mutagenesis and phage display methods with PfChBD2 as a template. A plasmid library was constructed by saturation mutagenesis of the PfChBD2 gene incorporated into a phage vector. A phage library displaying PfChBM2 mutants was created from the plasmid library using E. coli. Proteins with PET-binding ability were created by performing affinity selection of the phage library with pieces of amorphous PET film.

[0045] 2. Generation of PfChBD2-fADL-1e To create a PfChBD2 mutant that binds to PET, we first prepared a plasmid DNA that expresses a phage that displays PfChBD2 on its surface. The plasmid used for phage expression was fADL-1e. fADL-1e is a phage vector, and when fADL-1e with a target gene inserted therein is transformed into E. coli (SS320 strain), it is possible to express M13 phage that displays the target protein on its surface. A kanamycin resistance gene is incorporated into fADL-1e as a selection marker. In addition, a trypsin cleavage site was inserted between the PfChBD2 gene and the g3p protein gene to recover the phage that bound to PET. The PCR-amplified DNA encoding PfChBD2 and fADL-1e were ligated and transformed into phage-resistant E. coli (DH10B). The E. coli was cultured and the plasmid was extracted to obtain PfChBD2 plasmid DNA.

[0046] (1) PCR of PfChBD2 gene and plasmid (fADL-1e) <Method> 5 μL of template DNA, PfChBD2 gene and fADL-1e phage vector DNA solution (1 ng / μL), were mixed with 0.75 μL of 10 μM primer mix, and ultrapure water was added so that the total volume was 12.5 μL (Table 1). 12.5 μL of 2×KOD One PCR Master mix was added to the mixture, and PCR reaction was performed in a thermal cycler under the conditions of 98°C for 10 seconds and 68°C for 40 seconds for 30 cycles. The primers used are shown in Table 2. Loading Buffer was added to the PCR reaction solution sample, and the sample was applied to 2% and 1% agarose gel, respectively, and electrophoresed at 100V for 25 minutes. The gel was stained with MIDORI Green Xtra to confirm the band size. All bands were cut out from the gel and placed in a microtube. Gel extraction was performed using the Wizard (registered trademark) SV Gel and PCR Clean-Up System. The DNA concentration of the purified DNA sample was measured using an absorbance meter.

[0047] [Table 1]

[0048] [Table 2]

[0049] <Result> The expected DNA sizes are 384bp for PfChBD2 and 7950bp for fADL-1e. Bands were observed on the gel at around 400bp and 8kbp, respectively, indicating that the target genes had been amplified. Gel extraction yielded 25μL of DNA samples with DNA concentrations of 6.2ng / μL from PfChBD2 and 36.8ng / μL from fADL-1e.

[0050] (2) Ligation of PfChBD2 gene and plasmid (fADL-1e) and transformation <Method> The two DNA samples obtained in (1) were each added with 1 μL of NEBuilder HiFi DNA Assembly Master Mix and incubated in a thermal cycler at 50°C for 1 hour for ligation. 0.8 μL of the ligation reaction solution was mixed with 50 μL of electrocompetent cells (DH10B strain) and the mixture was placed in an electroporation cuvette. The DH10B strain is resistant to infection by bacteriophage. Electroporation was performed and 200 μL of SOC medium was added to suspend the cells. The suspension was collected in a microtube and incubated at 37°C at 1,000 rpm for 1 hour. The suspension was inoculated into LB agar medium supplemented with 50 μg / mL kanamycin and incubated at 37°C for 1 day. One colony was selected from the agar medium and inoculated into LB liquid medium supplemented with 50 μg / mL kanamycin and incubated at 37°C and 300 rpm for one day. The tube containing the bacterial culture was collected and centrifuged at 6,000 g for 3 minutes. The supernatant was removed, and plasmids were extracted from the precipitated E. coli using a QIAprep Spin Miniprep Kit. The DNA concentration of the purified plasmid was measured using an absorbance meter. To confirm that the target gene was accurately inserted into the plasmid, the purified plasmid DNA sample was sequenced. The sequence analysis was performed using Eurofins Genomics' DNA sequencing service.

[0051] <Result> We obtained 50 μL of plasmid DNA with a DNA concentration of 30 ng / μL. Furthermore, sequence analysis revealed that a single base had been inserted at the end of the inserted gene, and that the codon of the gene encoding the g3p protein, which is necessary for phage infection in fADL-1e, had shifted.

[0052] (3) PCR of PfChBD2 plasmid DNA <Method> Primers were designed to restore the gene encoding the g3p protein of the plasmid DNA sample obtained in (2) to the correct codon. Using the plasmid DNA obtained in (2) as template DNA, a PCR solution was prepared according to Table 1. PCR reaction was performed under the same conditions as in (1). The primers used are shown in Table 2. Loading Buffer was added, and the reaction solution sample was applied to a 1% agarose gel and electrophoresed at 100 V for 25 minutes. The gel was then stained with MIDORI Green Xtra to confirm the band size, and all the bands were excised from the gel and placed in a microtube. Gel extraction was performed in the same manner as in (1), and the DNA concentration of the purified DNA sample was measured using an absorbance meter.

[0053] <Result> The expected DNA size was 8318 bp. A band was observed on the gel at approximately 8 kbp, indicating that the target DNA had been amplified. Gel extraction yielded 25 μL of DNA sample with a DNA concentration of 35.6 ng / μL.

[0054] (4) Ligation and transformation of PfChBD2-fADL-1e <Method> 1 μL of the DNA sample obtained in (3) was mixed with 1 μL of NE Builder HiFi DNA Assembly Master Mix and incubated in a thermal cycler at 50°C for 1 hour to ligate the DNA sample. Transformation was performed in the same manner as in (2), and plasmid extraction was performed. The DNA concentration of the purified plasmid DNA was measured using an absorbance meter. The purified plasmid DNA sample was subjected to sequence analysis.

[0055] <Result> 50 μL of plasmid DNA with a DNA concentration of 124.7 ng / μL was obtained. In addition, sequence analysis showed that the PfChBD2 gene was inserted correctly and a plasmid with correct codons was obtained. The plasmid DNA obtained here is called PfChBD2-fADL-1e (Figure 1).

[0056] 3. Generation of PfChBD2-4M Plasmid Library Here, we used saturation mutagenesis to randomly mutate the codons corresponding to K270, N272, E279, and D281 of the PfChBD2 gene, and created a saturated mutant library of PfChBD2-4M. In saturation mutagenesis, primers are designed to introduce random mutations into the codons corresponding to the amino acid locus to be mutated, and PCR is performed. This PCR allows random codons to be generated for the codons corresponding to the target amino acid locus. When designing primers, the codon NNK was used to add random mutations to the codons. The bases A, T, G, and C are randomly synthesized from N, and the bases G and T are randomly synthesized from K. By using the codon NNK, the variation in the ratio of encoded amino acids is reduced, and 20 types of amino acids can be covered. In addition, the probability of the occurrence of a stop codon can be reduced to 3.125%.

[0057] (1) Introduction of mutations into PfChBD2 <Method> PfChBD2-fADL-1e was added to the template DNA (1 ng μL -1 ) and 0.75 μL of 10 μM primer mix, and ultrapure water was added to make the total volume 12.5 μL. 12.5 μL of 2xKOD One PCR Master mix was added to the mixture, and PCR reaction was performed in a thermal cycler under the conditions of 98°C for 10 seconds and 68°C for 40 seconds for 30 cycles. The primers used are shown in Table 3. Loading Buffer was added to the PCR reaction sample, which was then applied to a 1% agarose gel and electrophoresed at 100V for 25 minutes. The gel was stained with MIDORI Green Xtra to confirm the band size, and all the bands were excised from the gel and placed in a microtube. Gel extraction was performed as in Chapter 2 (1), and the DNA concentration of the purified DNA sample was measured.

[0058] [Table 3]

[0059] <Result> The expected DNA size is 8318bp. A band was observed on the gel at around 8kbp, indicating that the target DNA had been amplified. After gel extraction, 25μL of DNA sample with a DNA concentration of 19.1ng / μL was obtained. The DNA sample obtained here is designated PfChBD2-4M-fADL-1e.

[0060] (2) Ligation and transformation of PfChBD2-4M-fADL-1e <Method> The DNA sample obtained in (1) was added with an equal amount of NE Builder HiFi DNA Assembly Master Mix, and incubated in a thermal cycler at 50°C for 1 hour for ligation. 0.8 μL of the ligation reaction solution was mixed with 50 μL of electrocompetent cells (DH10B strain), and the mixture was placed in an electroporation cuvette. Electroporation was performed, and 200 μL of SOC medium was added and suspended. The suspension was collected in a microtube and incubated at 37°C and 1,000 rpm for 1 hour. The suspension was inoculated into LB agar medium containing 50 μg / mL kanamycin and incubated at 37°C for 1 day. This procedure was repeated until there were 10 agar medium plates. After counting the colonies that appeared on the agar medium, a platinum loop was used to collect all the colonies into liquid LB medium containing 50 μg / mL kanamycin, and the colonies were cultured overnight at 37°C and 1,000 rpm. 200 μL was collected from each of the 10 liquid mediums. Then, plasmid extraction and DNA concentration measurement were performed as described in Chapter 2(2).

[0061] <Result> The number of colonies that appeared on ten plates of LB agar medium supplemented with 50 μg / mL kanamycin is shown in Table 4. The number of colonies varied from plate to plate. The total number of colonies was 12,294. Plasmid extraction was performed, and 50 μL of a plasmid library with a DNA concentration of 31.4 ng / μL was obtained. The plasmid library obtained here is designated as generation 0 and is referred to as PfChBD2-4M-gene0.

[0062] [Table 4]

[0063] 4. Generation and Biopanning of the PfChBD2-4M Phage Library To select PfChBD2 mutants that bind to PET using phage display, we created a phage library by expressing and purifying phages that displayed PfChBD2 mutants on their surface. We then performed biopanning using the resulting phage library and PET film. In biopanning, rounds of binding to amorphous PET film pieces, washing, recovery, and growth were repeated with varying washing intensity and temperature. The SS320 strain was used as a host for phage expression. The SS320 strain is an E. coli strain that has the F factor and is suitable for constructing a phage library.

[0064] (1) Preparation of phage library PfChBD2-4M-gene0 phage generation 0 <Method> 0.5 μL of the PfChBD2-4M-gene0 plasmid library was mixed with 50 μL of electrocompetent cells (SS320 strain), and the mixture was placed in an electroporation cuvette. Electroporation was performed, and 200 μL of SOC medium was added to suspend the cells. The suspension was collected in a microtube and incubated at 37°C and 1,000 rpm for 1 hour. The suspension was inoculated into 2×YT liquid medium supplemented with 50 μg / mL kanamycin, and incubated at 37°C and 300 rpm for 1 day. 10 mL of bacterial culture was centrifuged at 13,000g for 5 minutes to precipitate E. coli. The supernatant was transferred to a new tube, and 5xPEG / NaCl was added to make the ratio of the supernatant to 5xPEG / NaCl 4:1. The tube was mixed by inversion and incubated on ice for 1 hour. The tube was centrifuged at 13,000g for 10 minutes to precipitate the phages. The supernatant was removed, centrifuged again, and the supernatant was completely removed. 120 μL of Tris Buffer Saline: 50 mM Tris-HCl (pH 7.5) was added to the precipitated phages, resuspended by vortexing, and incubated on ice for 1 hour. The tube was vortexed again and centrifuged at 13,000g for 1 minute to recover the phage solution. A blank was taken with 1x TBS buffer, and the absorbance was measured at 269 nm and 320 nm. The number of virions of the resulting phage solution was calculated using the following formula, assuming the length of the phage vector insert (8,303 bp) as the number of bases per virion.

[0065]

number

[0066] <Result> The absorbance of the phage solution after PEG precipitation is shown in Table 6. The number of phage virions was calculated from the difference in absorbance at 269 nm and 320 nm, which was 790 × 10 10 It was found that 120 μL of phage solution containing virions / mL was obtained. The phage obtained here was designated as PfChBD2-4M-gene0 phage.

[0067] (2) Preparation of bacterial cells (SS320 strain) <Method> SS320 was incubated in 2xYT liquid medium at 37°C, 250 rpm for 1 day. Culture medium was mixed with fresh 2xYT liquid medium at a ratio of 1:10, and incubated at 37°C, 250 rpm for 1 hour. Absorbance at 600 nm was measured and adjusted to 0.5-1.0. Phage was infected at room temperature for 1 hour.

[0068] (3) Biopanning <Method> In a 1.5 mL tube, 1 M sodium phosphate buffer (pH 8), the PfChBD2-4M-gene0 phage obtained in (1), and ultrapure water were added to obtain the composition shown in Table 5. The amorphous PET film used was prepared by cutting Good Fellow's 0.25 mm thick Amorphous PET firm into a disk with a diameter of 5.5 mm, adding it to 20% ethanol, washing at 20 rpm for 1 hour, rinsing with 20% ethanol, and drying.

[0069] [Table 5]

[0070] In the binding step, the solution containing the prepared amorphous PET film was incubated at 25°C and 1,000 rpm for 1 hour to bind the phage to the amorphous PET film. The supernatant was then transferred to a new tube and stored. In the washing step, 500 μL of 50 mM sodium phosphate buffer was added to perform washing, and the solution was incubated at 25°C and 1,000 rpm for 5 minutes. The washing solution was transferred to a new tube and stored. In one round, washing was performed five times, and the washing solution was collected each time and used as washing solutions 1 to 5. In order to elute the phage bound to the amorphous PET film, 500 μL of 0.25% trypsin solution was added and incubated at 37°C and 1,000 rpm for 20 minutes. The eluate containing the phage was stored in a new tube. Trypsin was also added to the supernatant and washing solution to a final concentration of 0.25%, and the solution was treated with trypsin.

[0071] In the infection and amplification step, the supernatant, washing solutions 1 to 5, and phage eluate were added in equal amounts to the SS320 culture solution obtained in (2), and the phage was infected into E. coli (SS320) for 30 minutes at 37°C and 1,000 rpm. The solution was appropriately diluted as necessary, inoculated onto 2xYT agar medium supplemented with 50 μg / mL kanamycin, and incubated at 37°C for one day (no dilution in the first round, 5-fold dilution of the culture solution containing washing solutions 1 and 2, and 2-fold dilution of washing solutions 3 to 5, and 5-fold dilution of washing solutions 4 and 5 in the third round). The number of colonies was then counted. The colonies that grew on the agar medium inoculated with E. coli infected with the phage eluate were all collected with a platinum loop into 2xYT liquid medium supplemented with 50 μg / mL kanamycin, and incubated at 37°C and 300 rpm for one day. The bacterial culture was centrifuged at 13,000g for 2 minutes to precipitate the E. coli. The supernatant was used for PEG precipitation to purify the phages. The precipitate was also used for plasmid extraction. The resulting phage and plasmid libraries were stored as new generations.

[0072] A total of three rounds were performed (Figure 2). In the second round, the new generation obtained in the previous round was used, and the number of washings was increased to 10, and the same procedure was performed again. In the next third round, the temperature conditions for incubation in the binding and washing steps were changed from 25°C to 60°C, and the same procedure as in the second round was performed. In the third round, colonies grown on the agar medium inoculated with E. coli containing the phage eluate were inoculated one by one into 2xYT liquid medium supplemented with 50 μg / mL kanamycin and incubated at 37°C and 1,000 rpm for one day. The bacterial culture was centrifuged at 13,000 g for 2 minutes, and the precipitate was used to extract plasmids. The obtained plasmid DNA was sequenced.

[0073] <Result> The absorbance of the phages obtained by PEG precipitation in the first and second rounds was measured. From the difference in absorbance at 269 nm and 320 nm, the length of the phage vector insert (8,303 bp) was calculated as the number of bases per virion, and the number of virions of the phage solution obtained in each round was calculated (Table 6). It was found that phages were obtained in each round. In addition, plasmid DNA was obtained from plasmid extraction performed in parallel.

[0074] [Table 6]

[0075] In the first round, 447 colonies were produced when E. coli infected with the eluted phages were inoculated onto 2xYT agar medium supplemented with 50 μg / mL kanamycin. The resulting colonies were collected and cultured, and the phages and plasmid DNA obtained by PEG precipitation and plasmid extraction were designated as one generation, with the phages designated as PfChBD2-4M-gene1 phage and the plasmid DNA designated as PfChBD2-4M-gene1. In addition, all agar plates inoculated with E. coli infected with the washings had so many E. coli that the colonies were indistinguishable.

[0076] In the second round, 972 colonies appeared when E. coli infected with the eluted phages were inoculated onto 2xYT agar medium supplemented with 50 μg / mL kanamycin. The resulting colonies were collected and bacterially cultured, and the resulting phages and plasmid DNA were designated as the second generation, with the phages designated PfChBD2-4M-gene2 phage and the plasmid DNA designated PfChBD2-4M-gene2. Colonies also appeared on all plates inoculated with E. coli infected with the wash fluid. Colony counting was performed on plates where colonies could be counted (Figure 3: 2xYT agar medium supplemented with 50 μg / mL kanamycin and the wash fluid (Wash) and eluate from rounds 2 and 3 were inoculated). -1 (Number of colonies formed on added 2xYT agar medium).

[0077] In the third round, 29 colonies were produced when E. coli infected with the eluted phages were inoculated onto 2xYT agar medium. Plasmids were extracted from each of the 29 colonies, and sequence analysis revealed the presence of three PfChBD2 mutants. The three mutants were PfChBD2-K270H-N272P-E279V-D281G, PfChBD2-K270T-N272P-E279L-D281R, and PfChBD2-K270P-E279L-D281W (different codon for N272), and the plasmid DNA of these mutants was stored as three generations (Figure 4). In addition, plasmid DNA of the PfChBD2-K270H-N272P-E279V-D281G mutant with the same codon was obtained from 27 of the 29 colonies.

[0078] <Consideration> It was confirmed that the colony forming units (cfu / mL) in the second round decreased from Wash 4 to 10 (Figure 3). In addition, the colony forming units of the second generation obtained in the second round were clearly larger than those of Wash 9 and 10, which suggests that the phages interacting with the amorphous PET film were recovered by the elution step. However, unlike the second round, the colony forming units of the third generation did not increase compared to Wash 9 and 10 in the third round. This is thought to be because the temperature conditions were stricter than in the second round, and more phages were removed by the washing step. Therefore, the mutants obtained in the third round may have higher heat resistance than the other mutants. In the third generation, three types of mutants were obtained from 29 colonies. The PfChBD2-K270H-N272P-E279V-D281G mutant was obtained from 27 of the 29 colonies. Therefore, the PfChBD2-K270H-N272P-E279V-D281G mutant may be more heat resistant than the other two mutants.

[0079] The three mutants PfChBD2-K270H-N272P-E279V-D281G, PfChBD2-K270T-N272P-E279L-D281R, and PfChBD2-K270P-E279L-D281W were obtained by affinity selection using the phage display method.

[0080] 5. Next Generation Sequencing Analysis To confirm the changes from the 0th generation plasmid library PfChBD2-4M-gene0 to the 2nd generation plasmid library PfChBD2-4M-gene2 by biopanning, next-generation sequencing analysis was performed on each library. In next-generation sequencing analysis, an extension reaction is performed on the prepared DNA library using a substrate nucleotide with a fluorescent substance, and a huge number of base sequences can be sequenced simultaneously by analyzing the library.

[0081] (1) Preparation of DNA samples for next-generation sequencing analysis <Method> Here, DNA samples were prepared for next-generation sequencing analysis by the MiSeq Paired-End method using the next-generation sequencer Illumina MiSeq. Plasmid library PfChBD2-4M-gene0 and PfChBD2-4M-gene2 obtained in round 2 were used as template DNA to amplify the DNA region containing the four mutation sites, and primers were designed to attach linker sequences to the ends (Table 7). PCR solutions were prepared according to Table 1. PCR reactions were performed in a thermal cycler under the conditions of 98°C for 10 seconds and 68°C for 40 seconds for 30 cycles. Loading Buffer was added, and the reaction solution samples were applied to 2% agarose gels and electrophoresed at 100V for 25 minutes. The gel was then stained with MIDORI Green Xtra to confirm the band size, and all the bands were excised from the gel and placed in a microtube. Gel extraction was performed as in Chapter 2 (1), and the DNA concentration of the purified DNA sample was measured. Then, electrophoresis was performed again on a 2% agarose gel to confirm whether the DNA was purified.

[0082] [Table 7]

[0083] The expected band size is 303 bp. A band was observed on the gel at around 300 bp, indicating that the target gene had been amplified. Gel extraction yielded 25 μL of DNA samples with DNA concentrations of 31 ng / μL from PfChBD2-4M-gene0 and 62 ng / μL from PfChBD2-4M-gene2. In addition, one band was observed in each of the purified DNA samples, confirming that the DNA samples were purified.

[0084] (2) Next-generation sequencing analysis <Method> The DNA sample purified in (1) was analyzed by the next-generation sequence analysis service of Hokkaido System Science Co., Ltd. The following shows that the analysis was performed by the next-generation sequence analysis service of Hokkaido System Science Co., Ltd. The concentration and quality of the samples were measured using an Agilent 2200 Tape Station system. Sequencing libraries were prepared according to Illumina's 16s Metagenomic Sequencing Library Preparation protocol. Using the next-generation sequencer Illumina MiSeq, base sequence data was obtained by reading 300 bases using the MiSeq Paired-End method. Text data of the base sequence was obtained from the output raw analysis data. Read data was selected by predetermined filtering. Each sample data was sorted according to index information. Read trimming was performed for each sample for the sorted data. Two read sequences were concatenated for the trimmed data. Read data of the same sequence was tabulated for the concatenated data. For the tabulated sequence data, target region excision and tabulation of identical sequences, amino acid translation and tabulation of identical sequences, and alignment of the target region were performed.

[0085] <Result> Table 8 shows the number of reads of the base sequences obtained by next-generation sequencing analysis and the number of unique amino acid sequences obtained by translation. The number of uniques was 17,791 in generation 0 and 3,827 in generation 2. In addition, the number of amino acid sequences with abnormalities in the number of amino acids due to the occurrence of stop codons or deletion or insertion of bases was 1,456 in generation 0 with 12,279 reads, and 259 in generation 2 with 424 reads. The true number of uniques was calculated from the difference between the number of uniques and the number of amino acid sequences with abnormalities in the number of amino acids. The true number of uniques was 16,335 in generation 0 and 3,568 in generation 2. It was found that the true number of uniques decreased from generation 0 to generation 2, and the number of types and reads of amino acid sequences with abnormalities in the number of amino acids decreased.

[0086] [Table 8]

[0087] Table 9 shows the top amino acid sequences counted from the next-generation sequencing analysis of each generation. In generation 0, many sequences that generated stop codons were ranked high. In addition, many wild-type (WT) amino acid sequences were also found in generation 0, which is thought to be due to the influence of the template DNA when adding mutations. The top counts in generation 2 were confirmed to have had a small number of reads in the next-generation sequencing analysis of generation 0. In addition, some of the top counts in generation 2 were not confirmed in the next-generation sequencing analysis of generation 0. This suggests that there were sequences that could not be read in the next-generation sequencing analysis of generation 0. However, it was found that even such sequences showed high counts in the next-generation sequencing of generation 2 by going through two rounds of biopanning.

[0088] [Table 9]

[0089] From the amino acid sequences obtained by next-generation sequencing analysis of generations 0 and 2, sequences with abnormal numbers of amino acids were removed, and the number of reads was counted. The amino acid distribution of generation 0 showed that mutations had been introduced by NNK. Comparing the amino acid distribution of generations 0 and 2, it was found that the amino acid distribution had changed due to the two rounds of biopanning.

[0090] The amino acid distribution in the second generation was different for each amino acid locus where mutations were added compared to the zero generation. At K270, the top three reads (%) were proline (P) at 64.7%, followed by threonine (T) and histidine (H) at 12% and 8.8%, respectively. At N272, the reads were proline (P) and methionine (M) at 22.3% and 22%, respectively, and histidine (H) at 13.5%. At N272, asparagine (N), which has a different codon from WT, accounted for 10.4%. At E279, the reads (%) were tryptophan (W) at 37.4%, followed by leucine (L) and valine (V) at 22% and 7.8%, respectively. At the D281 position, glutamic acid (E) accounted for 20.5% of the reads, followed by arginine (R) and tryptophan (W) at 15.3% and 13.3%, respectively, and glycine (G) and alanine (A) at 12.8% and 9.7%, respectively.

[0091] <Consideration> Next-generation sequencing analysis showed that the number of reads for sequences with abnormal numbers of amino acids in generation 0 was 12,279. As the total number of reads in generation 0 was 9,9136, it was found that the number of reads for sequences with abnormal numbers of amino acids accounted for 12.4%. When saturation mutagenesis was performed at four locations using NNK, stop codons were generated with a probability of 11.9%. In addition to stop codons, sequences with abnormal numbers of amino acids also included those with abnormal numbers of amino acids due to base deletions or insertions. For these reasons, it is believed that the number of reads for sequences with abnormal numbers of amino acids in generation 0 is close to the theoretical value. The number of reads with sequences with abnormal amino acid numbers was 12,279 in generation 0 and 424 in generation 2. This is thought to be because sequences with abnormal amino acid numbers were removed by biopanning, resulting in a decrease in the number of reads with sequences with abnormal amino acid numbers. The number of truly unique reads also decreased, from 16,335 in generation 0 to 3,568 in generation 2. This is also thought to be because PfChBD2 mutants that interact with amorphous PET films were selected by biopanning.

[0092] The top counts in the second generation included all of the PfChBD2 mutants from the third generation obtained in the third round (Table 9). In addition, the mutant with the highest count in the second generation was not confirmed in the third generation. This is because the binding and washing steps were performed at 25°C in the second round and 60°C in the third round. This is thought to be because combinations of mutations that result in low heat resistance were selected out even if they had a high count in the second round, and PfChBD2 mutants with highly heat-resistant structures were obtained in the third generation. Comparing the amino acid distributions of generations 0 and 2, the distribution changed for each amino acid locus where mutations were added, suggesting that a mutant library with improved PET binding ability had been obtained.

[0093] 6. Construction of stagRFP-PfChBD2 gene In order to confirm the binding ability of the third generation PfChBD2-K270H-N272P-E279V-D281G mutant, which was the most abundant mutant obtained in Chapter 4 (3), to amorphous PET, an expression system was constructed using E. coli as a host. The pET27b vector with a kanamycin resistance gene and a His tag was used as the protein expression vector. Using PCR and ligation reactions, the genes of PfChBD2 WT and mutants were inserted into plasmid DNA in which the fluorescent protein stagRFP and the TEV protease recognition sequence were inserted into pET27b. stagRFP is a red fluorescent protein with a maximum absorption wavelength of 555 nm and a fluorescence intensity approximately twice that of tagRFP-T. The ligated plasmid was transformed into E. coli Tuner (DE3) strain. The plasmid was extracted from the cultured E. coli, and the target gene was confirmed to be obtained by sequence analysis.

[0094] (1) PCR for generating stagRFP-PfChBD2 gene <Method> Primers were designed to insert the PfChBD2 gene into pET27b plasmid DNA into which the stagRFP gene and TEV protease recognition sequence had been inserted (Table 10). The pET27b plasmid DNA into which the stagRFP gene and TEV protease recognition sequence had been inserted and the DNA of the WT and K270H-N272P-E279V-D281G mutant of PfChBD2 were used as template DNA. Using the template DNA and primers, a PCR solution was prepared according to Table 1. PCR reaction was carried out in a thermal cycler under the conditions of 98°C for 10 seconds and 68°C for 40 seconds for 30 cycles. Loading Buffer was added to the PCR reaction solution sample, which was then applied to 2% and 1% agarose gels, and electrophoresed at 100V for 25 minutes. The gel was stained with MIDORI Green Xtra to confirm the band size. All bands were excised from the gel and placed in a microtube. Gel extraction was performed using the Wizard® SV Gel and PCR Clean-Up System. The DNA concentration of the purified DNA sample was measured using an absorbance meter.

[0095] [Table 10]

[0096] <Result> The expected DNA size was 6085bp for pET27b plasmid DNA with the stagRFP gene and TEV protease recognition sequence inserted, and 328bp for PfChBD2. Bands were observed on the gel at around 6kbp and 300bp, respectively, indicating that the target gene was amplified. Gel extraction yielded 25μL of DNA samples with DNA concentrations of 44.7ng / μL from the stagRFP gene, 161ng / μL from PfChBD2 WT, and 50ng / μL from PfChBD2-K270H-N272P-E279V-D281G.

[0097] (2) Ligation of stagRFP and PfChBD2 genes and transformation <Method> The DNA samples of stagRFP gene and PfChBD2 obtained in (1) were each 1 μL, and 2 μL of NEBuilder HiFi DNA Assembly Master Mix were added to make a total of 4 μL, and incubated at 50 °C for 1 hour in a thermal cycler for ligation. 0.8 μL of the ligation reaction solution was mixed with 50 μL of electrocompetent cell Tuner (DE3) strain, and the mixture was placed in an electroporation cuvette. The Tuner (DE3) strain is a lacZY deletion mutant that can induce protein expression depending on the concentration of IPTG (isopropyl β-D-thiogalactopyranoside). Electroporation was performed, and 200 μL of SOC medium was added and suspended. The suspension was collected in a microtube and incubated at 37 °C at 1,000 rpm for 1 hour. The suspension was inoculated into LB agar medium supplemented with 50 μg / mL kanamycin, and incubated at 37 °C for 1 day. One colony was selected from the colonies that formed on the agar medium, inoculated into LB liquid medium supplemented with 50 μg / mL kanamycin and agar medium, respectively, and incubated at 37°C and 300 rpm for one day. The tubes containing the bacterial culture were collected and centrifuged at 6,000 g for 3 minutes. The supernatant was removed, and plasmids were extracted from the precipitated E. coli using the QIA prep Spin Miniprep Kit. The DNA concentration of the purified plasmid was measured using an absorbance meter, and the plasmid DNA sample was sequenced.

[0098] <Result> A single colony was formed on LB agar medium supplemented with 50 μg / mL kanamycin. 50 μL of each plasmid DNA sample was obtained, with PfChBD2 (WT) inserted at a DNA concentration of 30 ng / μL and with PfChBD2-K270H-N272P-E279V-D281G inserted at a DNA concentration of 260 ng / μL. Sequence analysis showed that the PfChBD2 gene was inserted correctly. The plasmid DNA obtained here is called stagRFP-PfChBD2-TEV-His and stagRFP-PfChBD2-K270H-N272P-E279V-D281G-TEV-His (Figure 5).

[0099] 7. Expression and purification of stagRFP-PfChBD2 To perform binding experiments with amorphous PET using WT and K270H-N272P-E279V-D281G mutants of PfChBD2, we created WT and K270H-N272P-E279V-281G mutants of PfChBD2 fused with the fluorescent protein stagRFP at the N-terminus. The E. coli Tuner (DE3) strains incorporating stagRFP-PfChBD2-TEV-His and stagRFP-PfChBD2-K270H-N272P-E279V-D281G-TEV-His obtained in Chapter 6 were cultured in liquid medium, and the target protein was produced by inducing protein expression with IPTG. The produced proteins were purified using affinity chromatography and gel filtration chromatography.

[0100] (1) Expression of stagRFP-PfChBD2 and the stagRFP-PfChBD2-K270H-N272P-E279V-D281G mutant <Method> The colonies of stagRFP-PfChBD2-TEV-His and stagRFP-PfChBD2-K270H-N272P-E279V-D281G-TEV-His grown on the agar medium obtained in Chapter 6 (2) were inoculated into 10 mL of LB medium supplemented with 50 μg / mL kanamycin, and incubated at 37°C and 300 rpm for one day. The cultured bacterial liquid was inoculated into 700 mL of Super Broth medium supplemented with 50 μg / mL kanamycin, and incubated at 37°C and 130 rpm for three hours. After incubation, the medium was cooled in ice water for 30 minutes. 350 μL of 1M IPTG was added to each 700 mL of medium, and incubated at 20°C and 130 rpm for one day. Each medium was centrifuged at 3,000 g for 10 minutes to collect the precipitate. The precipitate was frozen and stored at -80°C.

[0101] <Result> The precipitate obtained was 6.1 g for stagRFP-PfChBD2-TEV-His and 3.0 g for stagRFP-PfChBD2-K270H-N272P-E279V-D281G-TEV-His. Both precipitates were red in color.

[0102] (2) Purification by affinity chromatography <Method> 10 mL of 50 mM sodium phosphate 100 mM sodium chloride buffer (buffer 1) was added to 10 g of the precipitate obtained in (1), and the precipitate was disrupted by an ultrasonic disrupter for 20 minutes. The disrupted solution was centrifuged at 20,000 g for 15 minutes, and the supernatant was collected. The supernatant was loaded onto a Ni-NTA column with a column volume of 3 mL, and the flow-through (FT) was collected. 130 mL of buffer was poured into the column, and 3 to 6 mL of the buffer that came out of the column was collected. Next, 30 mL of 50 mM imidazole, 50 mM sodium phosphate, and 100 mM sodium chloride buffer were poured into the column, and the same operation was performed. Then, 30 mL of 100 mM imidazole, 50 mM sodium phosphate, and 100 mM sodium chloride buffer were poured into the column, and 3 mL of each buffer was collected in a test tube. The absorbance of each buffer was measured, and the band size of the buffer that showed absorbance was confirmed by SDS-PAGE. Fractions in which bands were confirmed were collected in VIVASPIN20 (30,000 MWCO) and concentrated to 700 μL. The concentrated protein solution was replaced with Buffer 1 using illustra NAP-10 Columns to obtain 1.4 mL of protein solution. Then, 80 μL of 3 mg / mL TEV protease was added and incubated at 16 °C for 1 day. The protein solution was poured into Ni-NTA with a column volume of 0.5 mL. The sample that flowed out was poured into the column again and collected. Buffer 1 was poured in 500 μL at a time, and the protein solution that flowed out was collected for each, and the same operation was performed until a total of 3 mL of buffer 1 was poured. The absorbance of each fraction was measured, and those that showed absorbance at a wavelength of 280 nm were collected in VIVASPIN20 (30,000 MWCO) and concentrated by centrifugation until the protein solution was 500 μL or less.

[0103] <Result> The results of the absorbance measurement of each fraction obtained by affinity chromatography are shown in Table 11. The expected band size is 40 kDa. From the results of SDS-PAGE, a band was confirmed between 35 kDa and 45 kDa, indicating that the target protein was present in fractions No. 2 to 10. The absorbance of each fraction recovered using Buffer 1 after loading the TEV protease-treated protein solution onto a Ni-NTA column is shown in Table 12. Fraction No. 17 of the WT and fraction No. 14 of the K270H-N272P-E279V-D281G mutant were each concentrated to obtain 0.5 mL of protein solution.

[0104] [Table 11]

[0105] [Table 12]

[0106] (3) Purification by gel filtration chromatography <Method> Gel filtration chromatography was carried out using a Superdex 75 Increase 10 / 300GL column. The protein solutions obtained in (2) concentrated to less than 500 μL were loaded onto the columns. 50 mM sodium phosphate buffer (pH 8) was used as the buffer, and purification was carried out under the conditions of a flow rate of 0.5 ml / min and 0.5 mL per fraction. After purification, the band size of the fractions with absorbance was confirmed by SDS-PAGE. The fractions in which bands were confirmed were collected in a VIVASPIN20 (30,000 MWCO) and concentrated to less than 1 mL. The absorbance of the concentrated protein solution at 280 nm was measured using a spectrophotometer with a reference wavelength of 340 nm. The measured absorbance and the molar extinction coefficient (54,860 M -1 cm -1 ) to determine the protein concentration.

[0107] <Result> The expected band size was 40 kDa. A band was observed between 35 kDa and 45 kDa in SDS-PAGE, indicating that the target protein was purified. Fractions No. 5 to 19 for stagRFP-PfChBD2 and No. 3 to 16 for stagRFP-PfChBD2-K270H-N272P-E279V-D281G were collected and concentrated. Approximately 800 μL of stagRFP-PfChBD2 with a protein concentration of 40.9 μM and stagRFP-PfChBD2-K270H-N272P-E279V-D281G with a protein concentration of 25.9 μM were obtained.

[0108] 8. Measurement of binding amount to PET To confirm the PET binding ability of PfChBD2 (WT) and PfChBD2-K270H-N272P-E279V-D281G, the protein purified in Chapter 7 was incubated with amorphous PET. After centrifugation, the amount of protein in the supernatant was measured from the absorbance at the maximum absorption wavelength of 555 nm of the fluorescent protein stagRFP fused to PfChBD2 contained in the supernatant. The amount of protein bound per mg of substrate was calculated by measuring the absorbance of the substrate alone and the protein alone. In addition, the protein was quantified using the red fluorescent protein stagRFP because the substrate, amorphous PET, showed an absorption at 280 nm, which caused problems with the measurement accuracy.

[0109] (1) Preparation of a standard curve for stagRFP-PfChBD2 <Method> The stagRFP-PfChBD2 purified in Chapter 7 (3) was mixed with 50 mM sodium phosphate buffer (pH 8) to final concentrations of 0.5 μM, 1 μM, and 1.5 μM. The absorbance was measured and a standard curve was created from the results. In subsequent experiments, this standard curve was used to measure protein concentration.

[0110] (2) Measurement of binding ability of stagRFP-PfChBD2 and the stagRFP-PfChBD2-K270H-N272P-E279V-D281G mutant <Method> Solutions were prepared according to Table 13 using the purified stagRFP-PfChBD2 and stagRFP-PfChBD2-K270H-N272P-E279V-D281G obtained in Chapter 7 (3) and substrates. Amorphous PET was used as the substrate. Similarly, solutions containing only the substrate and only the protein were also prepared. In addition, three solutions were prepared for each solution. The prepared solutions were incubated at 25°C for 1 hour. The substrate was precipitated by centrifugation, and the absorbance of the supernatant was measured.

[0111] [Table 13]

[0112] <Result> From the absorbance measurement results, the concentrations of stagRFP-PfChBD2 and stagRFP-PfChBD2-K270H-N272P-E279V-D281G in each solution were calculated using the calibration curve obtained in (1). The amount of protein bound to the substrate (nmol) was calculated by taking the difference in protein concentration between the solution containing the substrate and protein and the solution containing only the substrate from the solution containing only the protein. The binding amount of stagRFP-PfChBD2 (WT) to amorphous PET was 0.3 (±0.64) nmol / mg, and that of the stagRFP-PfChBD2-K270H-N272P-E279V-D281G mutant was 3.87 (±0.86) nmol / mg (Figure 6).

[0113] <Consideration> Binding experiments showed that stagRFP-PfChBD2 (WT) hardly bound to amorphous PET. Using three generations of PfChBD2 mutants obtained by biopanning, stagRFP-PfChBD2-K270H-N272P-E279V-D281G acquired the ability to bind to amorphous PET.

[0114] The amino acid sequence (SEQ ID NO: 3) and gene sequence (SEQ ID NO: 4) of the stagRFP-PfChBD2-K270H-N272P-E279V-D281G mutant are shown in the table below. In the table below, the N-terminal portion (amino acids 1 to 244, bases 1 to 732) represents the red fluorescent protein stagRFP. The shaded portion (amino acids 245 to 247, bases 733 to 741) represents the linker sequence. The bold underlined portion at the C-terminus (amino acids 248 to 348, bases 742 to 1044) represents the PfChBD2 mutant. Boxed letters indicate the mutation points.

[0115] [Table 14]

[0116] The table below shows the mutation sites in the stagRFP-PfChBD2-K270H-N272P-E279V-D281G mutant. In this example, the mutated amino acid numbers (270, 272, 279, and 281) in the K270H-N272P-E279V-D281G mutant are shown as amino acid positions based on the chitinase from which PfChBD2 is derived. PfChBD2 is the C-terminal domain of chitinase, and the number of amino acids at the N-terminus is different between stagRFP-PfChBD2-K270H-N272P-E279V-D281G and chitinase. Therefore, the above amino acid numbers 270, 272, 279, and 281 correspond to the 260th, 262nd, 269th, and 271st amino acids from the N-terminus, respectively, in stagRFP-PfChBD2-K270H-N272P-E279V-D281G.

[0117] [Table 15]

[0118] In the above amino acid sequence, each mutation in the K270H-N272P-E279V-D281G mutant (i.e., the mutations at positions 260, 262, 269, and 271 from the N-terminus of SEQ ID NO: 3) corresponds to the K13H, N15P, E22V, and D24G mutations in PfChBD2, respectively.

[0119] 9. Summary In this study, we used the phage display method to create a protein with PET binding ability. In biopanning using a phage library, three PfChBD2 mutants were obtained as the third generation through three rounds. In addition, when the 0th generation before biopanning and the 2nd generation plasmid library obtained in the 2nd round were compared by next-generation sequencing analysis, the amino acid distribution changed at each amino acid locus where saturation mutations were introduced. In the 3rd round of biopanning, the PfChBD2-K270H-N272P-E279V-D281G mutant was the most frequently identified. Based on this, we assumed that the K270H-N272P-E279V-D281G mutant has higher heat resistance and PET binding ability than the other mutants, and performed a binding experiment with PET. In the binding experiment, the K270H-N272P-E279V-D281G mutant had acquired PET binding ability. These results indicate that it is possible to create proteins with PET binding ability by affinity selection with PET using the phage display method. This strategy may also be applied to improve the binding ability of the PfChBD2-K270H-N272P-E279V-D281G mutant to PET.

Claims

1. The amino acid sequence has 90% or more sequence identity with an amino acid sequence having the mutations K13H, N15P, E22V, and D24G relative to the amino acid sequence of SEQ ID NO: 1, and includes the amino acid sequence having the mutations K13H, N15P, E22V, and D24G; A protein having the ability to bind to polyethylene terephthalate.

2. The protein according to claim 1 , which has the ability to bind to polyethylene terephthalate at 60° C.

3. The protein of claim 1 , further comprising a labeling substance.

4. The protein according to claim 3 , wherein the labeling substance is a fluorescent dye or a fluorescent protein.

5. The protein of claim 1 , further comprising an enzyme domain.

6. The protein of claim 5 , wherein the enzyme domain is a polyethylene terephthalate degrading enzyme domain.

7. A polynucleotide comprising a base sequence encoding the protein according to any one of claims 1 to 6.

8. A recombinant vector comprising the polynucleotide of claim 7.

9. A transformant comprising the recombinant vector according to claim 8.

10. A composition comprising the protein according to any one of claims 1 to 6.

11. Contacting the protein according to claim 3 or 4 with polyethylene terephthalate; detecting the labeling substance; A method for detecting polyethylene terephthalate, comprising:

12. A method for degrading polyethylene terephthalate, comprising contacting the protein according to claim 6 with polyethylene terephthalate.

Citation Information

Patent Citations

  • Novel cutinase, gene encoding the cutinase, and method for decomposing polyester- or esther-compound by using the cutinase

    JP2015119670A

  • Novel esterase and its use

    JP2019527060A

  • Novel esterase derived from foliage compost

    WO2012099018A1

  • Enzymes for polymer degradation

    WO2019168811A1